Last reviewed · How we verify
Bupivacaine 0.25% Injectable Solution
Bupivacaine 0.25% Injectable Solution is a Small molecule drug developed by Zagazig University. It is currently FDA-approved. Also known as: Marcaine, Intrathecal Fentanyl, Ropivacaine 0.1% Injectable Solution, Fentanyl.
Bupivacaine 0.25% Injectable Solution, marketed by Zagazig University, is a well-established anesthetic in the healthcare sector. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the loss of exclusivity post-patent expiry, which could significantly impact revenue.
At a glance
| Generic name | Bupivacaine 0.25% Injectable Solution |
|---|---|
| Also known as | Marcaine, Intrathecal Fentanyl, Ropivacaine 0.1% Injectable Solution, Fentanyl, marcaine |
| Sponsor | Zagazig University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (PHASE4)
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- The Efficacy and Safety of Liposomal Bupivacaine for Rhomboid Intercostal Nerve Block in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery (NA)
- Comparison Of Clinical Outcomes of Intraperitoneal Bupivacaine Instillation Versus Placebo as Preemptive Analgesia in Patients Undergoing Open Appendectomy (PHASE1)
- Comparison of Erector Spinae Plane Block and Caudal Block in Pediatric Patients Aged 1 to 8 Years Undergoing Lower Abdominal Surgery (NA)
- Efficacy of Transversus Abdominis Plane Block in Alleviating Acute Appendicitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine 0.25% Injectable Solution CI brief — competitive landscape report
- Bupivacaine 0.25% Injectable Solution updates RSS · CI watch RSS
- Zagazig University portfolio CI
Frequently asked questions about Bupivacaine 0.25% Injectable Solution
What is Bupivacaine 0.25% Injectable Solution?
Who makes Bupivacaine 0.25% Injectable Solution?
Is Bupivacaine 0.25% Injectable Solution also known as anything else?
What development phase is Bupivacaine 0.25% Injectable Solution in?
Related
- Manufacturer: Zagazig University — full pipeline
- Also known as: Marcaine, Intrathecal Fentanyl, Ropivacaine 0.1% Injectable Solution, Fentanyl, marcaine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing